Filters

Apremilast manufacturers

13 products found

Filters

apremilast

Tablets, film coated 10mg, 20mg and 30mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Vietnam

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP

apremilast

Tablets 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Country of origin
European Union
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Chile, Vietnam, Peru

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Country of origin
Canada
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Pakistan, Vietnam

apremilast

Tablets, film coated 10mg, 20mg, 30mg ,

Dossier type
US CTD
Country of origin
Canada
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Pakistan, Vietnam

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Country of origin
India
Dossier status
Under Development
GMP approvals
EU GMP

apremilast

Tablets, film coated 30mg

Dossier type
EU CTD
Country of origin
India
Dossier status
Under Development
GMP approvals
EU GMP

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Country of origin
India
Dossier status
Under Development
GMP approvals
EU GMP
Unavailable markets
Chile, Panama

apremilast

Tablets 10mg, 20mg, 30mg

Dossier type
EU CTD
Country of origin
India
Dossier status
Under Development
GMP approvals
EU GMP

Apremilast:

Apremilast, also commonly known under the popular brand name of Otezla, is a medication used in the treatment of certain types of psoriasis and psoriatic arthritis. As well as also being effective in therapies for certain other immune system-related inflammatory diseases. In both the United States of America and the European Union, apremilast alone or in combination with disease-modifying antirheumatic drugs is indicated for active psoriatic arthritis, for which it is predominantly prescribed. Originally patented by a pharmaceutical products company, apremilast manufacturers and apremilast suppliers have since gained it regulatory approval by the FDA in 2014 and by the European Union in 2015 for use in this treatment. Currently, apremilast has also been approved for use in treating oral ulcers associated with Bechet’s disease and can be found produced by manufacturers for sale on the global marketplace. Where it is frequently on the wholesale pharmaceutical products list of distributors, being available for order at a variety of cost and price points.

Method of action of apremilast:

Apremilast belongs to a group of drugs which serves as phosphodiesterase 4 inhibitors. Although the full mechanism of action is still not fully established, it is thought to function through the phosphodiesterase 4 mediated disruption of cyclic adenosine monophosphate. This increases cyclic adenosine monophosphate intracellular levels, resulting in the suppression of inflammation by decreasing the expression of TNF-α, IL-17, IL-23, and other inflammatory mediators. Which are reasonable for symptomatic inflammatory effects such as mouth ulcers, skin lesions, and arthritis. Therefore, the administration of apremilast culminates in a cascade which leads to a decrease in of the above mediators, relieving inflammatory symptoms.

Form and dosage of apremilast:

The final form and packaging of apremilast is dependent on the manufacturers and suppliers, as well as the specific order and distributors. However, apremilast predominantly comes in tablet and film-coated tablet form, which is taken orally. It is a prescription medication, as such, it can only be taken with the approval of a healthcare professional. The typical dosage defers to the opinion of the prescribing professional and is dependent on the particular individual and underlying condition being treated. Caution is advised by manufacturers in patients that have a history of psychiatric illness, as use has a probability of causing psychiatric symptoms and drastic weight loss.

Apremilast on Pipelinepharma:

Currently, at the time of writing, we have found 10 verified apremilast manufacturers and apremilast suppliers from our online global list of B2B sellers. These manufacturers, suppliers, and distributors have apremilast available for wholesale order and are located in various countries including India, Canada, the European Union, and Argentina. Each company listed on our online marketplace has been verified by the Pipelinepharma team according to strict quality control. This ensures the reputability of the seller and limits buyer mileage, making for an easier transaction experience for all B2B parties.

Price of Apremilast and how to buy:

The typical price of apremilast is dependent on numerous factors including organisation, market, and quantity. However, a cursory search online reveals an approximate cost for wholesale apremilast is priced at USD 716.71 for 56×30 mg tablets. These values are for sale to the UK’s national health service, as such, they serve only as approximations for the current market situation. Although the prices on the B2B wholesale Pipelinepharma marketplace remain confidential between both B2B parties, the seller may choose to list a desired price to facilitate the online transaction. If so, an ‘Accept’ and ‘Negotiate’ button will be displayed through the online interface, with a ‘Get offer’ button being shown in the absence.